Related Experiment Video
Updated: Jun 1, 2026
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
[Cost-effectiveness analysis of pneumococcal vaccination in Spain]
Raúl Morano1, Ferrán Pérez, Max Brosa
1Departamento de Evaluación de Medicamentos, GlaxoSmithKline, Tres Cantos, Madrid, España. raul.l.morano-larragueta@gsk.com
Insights
Pediatric pneumococcal vaccination with Synflorix® in Spain is more cost-effective than Prevenar13®. Synflorix® offers more quality-adjusted life years (QALYs) and significant cost savings for the health system.
Area of Science:
- Public Health
- Health Economics
- Pediatrics
Background:
- Pneumococcal disease poses a significant health burden in children.
- Vaccination strategies are crucial for disease prevention and health system efficiency.
Purpose of the Study:
- To conduct a cost-effectiveness analysis of pediatric pneumococcal vaccination in Spain.
- Compare the cost-effectiveness of Synflorix® versus Prevenar13® in children under two years old.
Main Methods:
- A deterministic, population-based decision-tree model with a 1-year time horizon was utilized.
- Epidemiological and cost data were sourced from national databases and literature.
- Outcomes included prevented cases of invasive pneumococcal disease, acute otitis media (AOM), and pneumonia hospitalizations, measured in quality-adjusted life years (QALYs).
Main Results:
- Synflorix® demonstrated potential to prevent an additional 41,513 AOM episodes, 36,324 antibiotic prescriptions, and 382 myringotomy procedures compared to Prevenar13®.
- This resulted in an additional 143 QALYs gained with Synflorix®.
- The total vaccination cost using Synflorix® was projected to yield savings of 22 million euros.
Conclusions:
- Pneumococcal vaccination with Synflorix® in young children in Spain is a dominant cost-effective strategy.
- Synflorix® offers superior cost-effectiveness, achieving more QALYs and significant cost offsets compared to Prevenar13®.
Objective:
To perform a cost-effectiveness analysis of pediatric pneumococcal vaccination in Spain.
Methods:
A deterministic population-based model in the form of a decision-tree with a 1-year time horizon was used to estimate the impact of vaccination with Synflorix® or Prevenar13® in children aged less than 2 years in Spain from the perspective of the National Health System. Epidemiological data were obtained from the hospital discharge minimum data set (MDS) and the literature. Data on costs were obtained from national health costs databases. The main outcomes measured were the number of cases avoided of invasive pneumococcal disease, acute otitis media (AOM) and myringotomies, and hospital admissions for pneumonia. All costs were expressed in 2010 euros. Effectiveness was measured as the number of quality-adjusted life years (QALYs) gained.
Results:
The efficacy of Synflorix® in preventing episodes of AOM caused by non-typeable Haemophilus influenzae could lead to additional prevention of 41,513 episodes of AOM, 36,324 antibiotic prescriptions and 382 myringotomy procedures and 143 QALYs gained compared with Prevenar13®. The total vaccination cost with Synflorix® would result in savings of 22 million euros.
Conclusions:
Pneumococcal vaccination with Synflorix® in comparison with Prevenar13® in children aged less than 2 years old in Spain could achieve a higher number of QALYs and a substantial cost offset. Vaccination with Synflorix® would be a dominant strategy in terms of cost-effectiveness.
Related Concept Videos
01:28Antimicrobial Effectiveness
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:30Pneumonia III: Complications and Assessment
01:51Vaccinations
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Pneumonia II: Pathophysiology